DANIELA KANTCHEVA: Open Payments
NPI 1124072350 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,631 in 176 payments from 13 companies in 2025. Trend: 2023 $972 · 2024 $1,262 · 2025 $2,631
Food & beverage: $2,629Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $557 |
| Neurocrine BioSciences, Inc. | 19 | $327 |
| Alkermes, Inc. | 19 | $309 |
| Otsuka America Pharmaceutical, Inc. | 18 | $291 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $243 |
| Vanda Pharmaceuticals Inc. | 17 | $217 |
| Janssen Pharmaceuticals, Inc | 13 | $183 |
| E.R. Squibb & Sons, L.L.C. | 20 | $170 |
| Lundbeck LLC | 9 | $152 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
Products named: VRAYLAR, INGREZZA, REXULTI, ARISTADA, CAPLYTA, FANAPT, COBENFY, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
